Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BGM GroupBGM +0.71%36 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates BGM with a GF Score™ of 36/100 and a GF Value™ of $0.40 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 811 Drug Manufacturers companies, BGM Group ranks worse than 123304.44% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BGM Group's Debt-to-Equity or its related term are showing as below:
During the past 9 years, the highest Debt-to-Equity Ratio of BGM Group was 0.62. The lowest was 0.00. And the median was 0.10.
BGM's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.28 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
BGM Group Debt-to-Equity Related Terms
BGM Group Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for BGM Group's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGM vs CPIX, ADCT, LFCR: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BGM Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BGM Group Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BGM Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BGM Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGM Group (BGM) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BGM Group and its competitors. According to the industry distribution chart, BGM Group ranks #999999 out of 811 companies in the Drug Manufacturers industry.
Is BGM Group's Debt-to-Equity too high?
BGM Group's current Debt-to-Equity is 0.00. Based on the distribution chart, BGM Group ranks #999999 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BGM Group has a GF Score™ of 36/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BGM Group's Debt-to-Equity compare to CPIX and ADCT?
According to the Drug Manufacturers industry distribution chart, BGM Group ranks #999999 out of 811 companies for Debt-to-Equity. This places BGM Group in the lower half of its industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BGM Group and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BGM Group's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BGM Group stock overvalued right now?
Based on GuruFocus' analysis, BGM Group (BGM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.40, compared to a current price of $0.29 — trading 28.8% below its estimated fair value. The current Debt-to-Equity is 0.00. BGM Group's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BGM Group (BGM), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BGM Group (BGM) Overvalued in 2026?
Based on GuruFocus' analysis, BGM Group stock appears to be undervalued.
The current stock price of $0.29 is trading 28.8% below its estimated GF Value™ of $0.40.
GuruFocus considers BGM Group to be Modestly Undervalued.
Key valuation signals for BGM:
Debt-to-Equity: 0.00
GF Value™: $0.40 vs. price of $0.29 (28.8% below fair value)
No single metric tells the full story. See the BGM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
36GF Score
Get the complete analysis for BGM
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGM has been successfully added to your 
